THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

GLIOMATCH results contribute to new EIC-funded project GLIOBREAK

Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.

Exploiting GLIOMATCH results for clinical development

Results generated within the GLIOMATCH project are contributing to the advancement of innovative therapeutic strategies for glioblastoma.

The newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics together with GLIOMATCH partner LISCO – KU Leuven Institute for Single Cell Omics, builds directly on findings obtained within GLIOMATCH.

GLIOBREAK will advance BEA-17, a first-in-class LSD1–CoREST degrader, alongside the development of a companion diagnostic. The project aims to bring the programme to clinical readiness, including the completion of IND-enabling studies and preparation for regulatory submission.

The consortium has secured EUR 2.5 million in funding from the European Innovation Council to support these next steps towards clinical development.

Read the full press release here.

Follow GLIOMATCH on LinkedIn and Facebook for more information on brain tumour research and updates on our milestones towards improving the clinical outcomes of GBM and pHGG.

More Posts

International Childhood Cancer Day 2026

On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.

International Day of Women and Girls in Science 2026

GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.

World Cancer Day 2026

On World Cancer Day 2026, GLIOMATCH highlights the importance of placing patient perspectives at the heart of cancer research, particularly for glioblastoma, one of the most aggressive and difficult-to-treat brain tumours.

GLIOMATCH 3rd consortium meeting takes place in Düsseldorf, Germany

From 25 to 27 March 2025, the GLIOMATCH consortium convened in Düsseldorf, Germany, for its third consortium meeting. The meeting was held in-person and hosted by the partner University of Düsseldorf (UDUS). Over 40 experts from across Europe gathered to assess progress of the past year and plan the next phase of the GLIOMATCH project.